WuXi Biologics, delivered a keynote address at the 43rd J.P. Morgan Healthcare Conference, providing an insightful look into the company’s latest achievements, strategies, and future outlook. His presentation highlighted WuXi…
UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan…
Walgreens Steps Up Amid the ‘Quad-Demic’: Vaccines, Testing, Treatments, and Support The term “tripledemic” gained traction not too long ago to describe the simultaneous surges of flu, COVID-19, and respiratory…
Incyte and Syndax Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The companies expect the product to…
Unprecedented challenges such as conflict, climate change, epidemics, and displacement are converging to create a severe global health crisis, leaving 305 million people in dire need of humanitarian assistance in…
The Nomination Committee of Orion Corporation has provided its recommendations to the company’s Board of Directors regarding proposals for the 2025 Annual General Meeting (AGM). These recommendations address both the…
Pheno Therapeutics Receives Clinical Trial Authorization for MS Candidate PTD802 Pheno Therapeutics Limited, a leading biotechnology company focused on developing small molecule therapeutics for neurological diseases, has received Clinical Trial…
Bayer’s Pharma Growth Strategy Advances as Pipeline Progresses At the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG revealed significant advancements in its pharmaceutical growth strategy, announcing multiple…
First Participants Enrolled in AskBio Phase II Gene Therapy Trial for Parkinson’s Disease AskBio Inc., a leading gene therapy company and a subsidiary of Bayer AG, announced today that the…
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical…
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination…
Datopotamab Deruxtecan Granted Priority Review by FDA for Advanced EGFR-Mutated NSCLC AstraZeneca and Daiichi Sankyo recently announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License…
